Thomas J. Kaley, MD
Neuro-Oncologist & Early Drug Development Specialist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- Neuro-Oncology
- Adult Primary Brain Tumors (including Glioblastoma, Gliomas, Low-Grade Glioma, Anaplastic Glioma, Meningioma, Ependymoma, and other Rare Tumors)
- Brain Metastases
About Me
- Vice Chair for Clinical Research, Department of Neurology
- Chair, Institutional Review Board (IRB-C)
I am a neuro-oncologist who specializes in the care of patients with brain tumors and the neurologic complications of cancer. My team of physicians, nurses, research staff, and administrative support works with patients to deliver effective and compassionate specialized care for adult primary brain tumors, including:
- Glioblastomas
- Gliomas (low-grade gliomas and anaplastic gliomas)
- Meningioma
- Ependymomas
- Other rare tumors
I also treat brain metastases that have spread from other solid cancers in the body.
Read more
I am currently conducting clinical trials and research for glioblastomas and other primary brain tumors in both the upfront and recurrent settings. My research also focuses on the treatment of patients with both benign and aggressive meningiomas, specifically investigating chemotherapy and molecularly targeted therapy when surgery and radiation are not an option.
In addition to treating patients, I serve as Vice Chair for Clinical Research in the Department of Neurology and the Chair of the Institutional Review Board (IRB-C), where I oversee departmental and institutional research portfolios at MSK. I also have a firm commitment to teaching and mentoring national and international neuro-oncology fellows, junior faculty, residents, and house staff.
A neuro-oncologist is a doctor with special training in cancers that affect the brain, spinal cord, peripheral nerves, and muscles. This includes brain tumors and central nervous system tumors.
An early drug development specialist tests new drugs to treat cancer. They have special training in research studies, known as clinical trials.
My Specialties
- Neuro-Oncology
- Adult Primary Brain Tumors (including Glioblastoma, Gliomas, Low-Grade Glioma, Anaplastic Glioma, Meningioma, Ependymoma, and other Rare Tumors)
- Brain Metastases
- Central Nervous System Lymphoma
- Neurological Complications of Cancer
Education
- MD, New York University
Residencies
- Neurology - New York University School of Medicine
Awards and Honors
- Castle Connolly: America’s Top Doctor (2024)
- Top Doctors New York Metro Area, Castle Connolly (2019-2023)
- Castle Connolly: America's Top Doctors (2019-2023)
Fellowships
- Neurology - Memorial Sloan Kettering Cancer Center
Board Certifications
- Neurology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
PPO, HMO, DSN
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
Contact and Location
Dr. Kaley sees patients at two locations.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Kaley
- A Phase 2 Study of Erdafitinib for Progressive Brain Cancers With a Gene Fusion
- A Study Exploring New Therapies for Newly Diagnosed Glioblastoma
- Access to Vorasidenib for the Treatment of Glioma
- Clinical Trials Co-Investigated by Dr. Kaley
- A Phase 1 Study of Debio 0123 With Temozolomide for People With Glioblastoma
Read more
- A Phase 1 Study of rQNestin34.5v.2 in People With Glioma
- A Phase 1 Study of TNG908 in People with Sarcoma, Mesothelioma, or Glioblastoma
- A Phase 1/2 Study of AMG 193 Plus IDE397 to Treat Advanced Digestive Cancers Lacking the MTAP Protein
- A Phase 1/2 Study of AZD9574 Alone and With Other Anti-Cancer Drugs in People with Glioma
- A Phase 2 Study of Pembrolizumab Immunotherapy, Olaparib, and Temozolomide in People With Glioblastoma
- A Phase I Study of Vorasidenib with Pembrolizumab Immunotherapy for Recurrent or Persistent IDH-1 Mutant Astrocytomas
- A Phase II Study of Pembrolizumab Immunotherapy, Olaparib, and Temozolomide in People with Recurrent Glioma
- A Phase II/III Study of Regorafenib, Paxalisib, and VAL-083 versus Standard Therapy for Patients with Newly Diagnosed or Recurrent Glioblastoma (GBM AGILE)
- A Study of L19TNF Plus Lomustine in People With Brain Cancer
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Kaley’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Thomas J. Kaley discloses the following relationships and financial interests:
-
Servier
Professional Services and Activities
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].